Transgene is at the forefront of developing next-generation immunotherapeutics aimed at combating cancer through innovative technologies. One of their key platforms is myvac®, which focuses on creating individualized neoantigen cancer vaccines, such as TG4050. This personalized approach utilizes advanced genetic engineering and artificial intelligence to tailor vaccines to the unique tumor profiles of individual patients. TG4050 is currently undergoing clinical trials for head and neck cancers, where it aims to stimulate a targeted immune response against patient-specific neoantigens, thereby enhancing the body’s ability to destroy cancer cells.

In addition to personalized vaccines, Transgene employs oncolytic viruses (OVs) through its invir.IO® platform. These multifunctional OVs are designed to selectively replicate within cancer cells, leading to cell lysis while simultaneously activating the immune system against tumors. Notable candidates from this platform include BT-001, which combines an anti-CTLA4 antibody and GM-CSF to enhance immune response, and TG6050, engineered to express interleukin-12 and an anti-CTLA4 antibody. Both candidates are in clinical trials, showcasing Transgene's commitment to harnessing the immune response for effective cancer treatment through a combination of therapeutic vaccines and oncolytic virus technologies.

France

Cancer immunotherapy
  
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.

Cancer

Digestive System Diseases

Infectious Diseases

Urogenital Diseases

Transgene

Head and neck cancer

Ovarian cancer

TG4050

Biologics

Gene Therapy

Vaccines

Human Papillomavirus

TG4001

Colorectal cancer

Stomach Cancer

TG6002

Solid tumor/s

BT-001

Non-small cell lung carcinoma

TG6050

Europe - West

Antibodies

Antiviral Therapies

Artificial Intelligence

Cell Therapies

Therapeutic

Transgene

Company Details